Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms
Maria Pinkerneil, Michèle J. Hoffmann, René Deenen, et al.
Molecular Cancer Therapeutics (2016) Vol. 15, Iss. 2, pp. 299-312
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Lysine acetylation and cancer: A proteomics perspective
Jeovanis Gil, Alberto Ramírez-Torres, Sergio Encarnación
Journal of Proteomics (2016) Vol. 150, pp. 297-309
Closed Access | Times Cited: 165
Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells
Anna Wawruszak, Joanna Kałafut, Estera Okoń, et al.
Cancers (2019) Vol. 11, Iss. 2, pp. 148-148
Open Access | Times Cited: 90
HDAC2 as a target for developing anti-cancer drugs
Hyein Jo, Kyeonghee Shim, Hanul Kim, et al.
Computational and Structural Biotechnology Journal (2023) Vol. 21, pp. 2048-2057
Open Access | Times Cited: 32
Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer
Bi Lian, Xiaosong Chen, Kunwei Shen
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
Effects of novel HDAC inhibitors on urothelial carcinoma cells
Aline Kaletsch, Maria Pinkerneil, Michèle J. Hoffmann, et al.
Clinical Epigenetics (2018) Vol. 10, Iss. 1
Open Access | Times Cited: 74
Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
Makoto Isono, Michèle J. Hoffmann, Maria Pinkerneil, et al.
Journal of Experimental & Clinical Cancer Research (2017) Vol. 36, Iss. 1
Open Access | Times Cited: 68
Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines
Alexander Sebastian Hölscher, Wolfgang A. Schulz, Maria Pinkerneil, et al.
Clinical Epigenetics (2018) Vol. 10, Iss. 1
Open Access | Times Cited: 64
Targeting histone modifiers in bladder cancer therapy — preclinical and clinical evidence
Shiyu Zhang, Tianhai Lin, Xingyu Xiong, et al.
Nature Reviews Urology (2024) Vol. 21, Iss. 8, pp. 495-511
Closed Access | Times Cited: 7
Association of Smoking, Alcohol Use, and Betel Quid Chewing with Epigenetic Aberrations in Cancers
Tong‐Hong Wang, Shih‐Min Hsia, Yin-Hwa Shih, et al.
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 6, pp. 1210-1210
Open Access | Times Cited: 60
Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
Maria Pinkerneil, Michèle J. Hoffmann, Hella Kohlhof, et al.
Targeted Oncology (2016) Vol. 11, Iss. 6, pp. 783-798
Open Access | Times Cited: 55
Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer
Aikaterini F. Giannopoulou, Athanassios D. Velentzas, Eumorphia G. Konstantakou, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 6, pp. 1291-1291
Open Access | Times Cited: 53
Differential molecular mechanistic behavior of HDACs in cancer progression
Tashvinder Singh, Prabhsimran Kaur, Paramdeep Singh, et al.
Medical Oncology (2022) Vol. 39, Iss. 11
Closed Access | Times Cited: 25
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes
Petros Grivas, Amir Mortazavi, Joel Picus, et al.
Cancer (2018) Vol. 125, Iss. 4, pp. 533-540
Open Access | Times Cited: 43
Proteomic analysis of the urothelial cancer landscape
Franz F. Dressler, Falk Diedrichs, Deema Sabtan, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Amyloids in bladder cancer hijack cancer-related proteins and are positive correlated to tumor stage
Diego Alem, César X. García-Laviña, Francisco Garagorry, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors
Michèle J. Hoffmann, Evangelia A. Koutsogiannouli, Margaretha A. Skowron, et al.
Bladder Cancer (2016) Vol. 2, Iss. 4, pp. 449-463
Open Access | Times Cited: 38
Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
Camilla M. Grunewald, Corinna Haist, Carolin König, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 25
Discovery of Selective Histone Deacetylase 1 and 2 Inhibitors: Screening of a Focused Library Constructed by Click Chemistry, Kinetic Binding Analysis, and Biological Evaluation
Yukihiro Itoh, Peng Zhan, T Tojo, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 22, pp. 15171-15188
Closed Access | Times Cited: 9
Androgen receptor suppresses prostate cancer metastasis but promotes bladder cancer metastasis via differentially altering miRNA525-5p/SLPI-mediated vasculogenic mimicry formation
Yang Zhao, Jiaqi Chen, Hongjun Xie, et al.
Cancer Letters (2019) Vol. 473, pp. 118-129
Open Access | Times Cited: 28
Histone deacetylase inhibitors as cancer therapeutics
Gary A. Clawson
Annals of Translational Medicine (2016) Vol. 4, Iss. 15, pp. 287-287
Open Access | Times Cited: 27
Contingencies of UTX/KDM6A Action in Urothelial Carcinoma
Alexander Lang, Merve Yılmaz, Christiane Hader, et al.
Cancers (2019) Vol. 11, Iss. 4, pp. 481-481
Open Access | Times Cited: 26
Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC)
Kuojun Zhang, Zhiyi Liu, Yiwu Yao, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 7, pp. 4020-4033
Closed Access | Times Cited: 20
Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells
Michèle J. Hoffmann, Sarah Meneceur, Katrin Hommel, et al.
Genes (2021) Vol. 12, Iss. 2, pp. 260-260
Open Access | Times Cited: 18
Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma
Margaretha A. Skowron, Anuja Sathe, Andrea Romano, et al.
Urologic Oncology Seminars and Original Investigations (2017) Vol. 35, Iss. 9, pp. 544.e11-544.e23
Closed Access | Times Cited: 24
Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems
Jenna Buckwalter, Wilson Chan, Lauren Shuman, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 10, pp. 2599-2599
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top